

Translating cancer biology into medicines Noble Capital Markets Conference

2 2

NASDAQ CYCC - January 30, 2018

Disclaimer

CYCLACEL

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forwardlooking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at <u>www.sec.gov</u>. The information in this presentation is current as of this date. Cyclacel does not take any responsibility to update such information.



\$107 bn in 2015 (+12% YoY). *Est.* ~\$150 bn in 2020.

Price hikes, \uparrow patient #, **longer duration of therapy**

Avg. annual patient out-of-pocket: **\$7k iv, \$3k oral Rx**

Major threat to this colossal investment:

RESISTANCE TO CANCER Rx

* Source: Aitken M, Kleinrock, M, IMS Institute for Healthcare Informatics, June 2, 2016.



Single Rx targeting mutations: validated approach

↑ response but few cures/long stable disease

EVOLUTION OF RESISTANCE OR ADDICTION TO CANCER GENES

- Strategy: combine approved Rx that is no longer working with resistance-modifying Rx or
- Rx that breaks addiction



Our solution: Cyclin Dependent Kinase CDK Inhibitors



2001 Nobel Prize for Physiology & Medicine (*CDKs & cyclins*)

3 approved CDKi:

- IBRANCE® (palbociclib, PFE, approved 2015, ~\$3.3bn 2017E)
- 2017: KISQALI[®] (ribociclib, NVS), VERZENIO[®] (abemaciclib, LLY)
- CDK4/6 inhibitors → senescence → eventually resistance

CDK2/9i strategy: overcome **resistance** by lowering killing threshold

CYC065 2nd Gen, highly potent, improved Rx profile (Ph 1)



In many cancers resistance correlates with:

- ↑ pro-survival protein expression, such as Bcl-2, Bcl-XL, Mcl-1
- addiction to oncogenes, such as MYC, cyclin E

First Bcl-2 Rx: venetoclax (ABBV, CLL); does not \downarrow Mcl-1

Competitive race to develop Mcl-1 inhibitors

• CYC065 1st CDK inhibitor Rx: durable \downarrow Mcl-1 in patients



n=26 heavily pretreated patients with advanced

solid tumors (13 in DL6 cohort RP2D)

- Durable Mcl-1 suppression >24h after single dose in 11/13 evaluable DL6 patients
- Anticancer activity in 6/13 patients (5 at RP2D)

CYC065: Clinical Development Priorities

Molecularly-defined patient populations



Hematological malignancies:

Combination with venetoclax, i.e. relapsed/ refractory CLL (incl. Mcl-1 个)

Solid tumors:

- 2 Selected Mcl-1 个 or MYC 个 solid tumors, i.e. neuroblastoma, ovarian, etc.
- 3 Selected Cyclin E 个 solid tumors, i.e. breast, uterine (USC)



Rare ped. Dx; 90% children <5y; few survive >10y

MYCN amplification ~40-50% of high risk NB

CYC065 rare investigational Rx to show activity in

adult patients with MYCN amplification

Discussions with KOLs ongoing

* Source: Cyclacel data on file.



CDK4/6 isoform

palbociclib (PFE), ribociclib
(NVS), abemaciclib (LLY)
Approved in combination with
letrozole for ER +ve Her2 -ve
advanced or met BC

trilaciclib (GTHX) Ph1/2

CDK2/9 transcriptional isoform CYC065 (CYCC 2G) Ph1 seliciclib (CYCC 1G) Ph2 dinaciclib (pan CDK, MRK) Ph3 BAY1143572 (CDK9, BAY) Ph1 **Other** (pan CDK or selective): **SY1365** (CDK7, Syros); voruciclib (CDK4/6/9, MEI Pharma)



DNA Damage Response (DDR) Clinical Program

DNA Damage Response (DDR):

Overcoming Cancer DNA Repair & Evasion



Cancer cells evade Rx; block DNA repair; ultimately become immortal

SoC HR deficient cancers (incl. BRCA): PARP inhibitors in ~ 50% of patients

CYCC DDR strategy: combine CDKi + sapacitabine

- CDKi modulate DNA repair via HR, NHEJ; scpression of HR DNA repair genes incl. BRCA; disrupts cyclin E amplification
- Sapacitabine active in patients with BRCA +ve (HR def) cancers
- Encouraging clinical data (n=76) reported at ASCO

Sapacitabine & Seliciclib Phase 1 Best Responses*



RECIST Evaluable BRCA Carriers

Cancer	Best Response	Prior Treatment		
Part 1	(n=16)			
Breast	CR	adriamycin, cyclophosphamide, paclitaxel, cisplatin	>80	
Breast	PR	adriamycin, cytoxan, paclitaxel, carboplatin	31	
Ovary	SD	paclitaxel, carboplatin, gemcitabine		
Ovary	PR	paclitaxel, carboplatin, gemcitabine, topotecan, iniparib		
Breast	SD	tamoxifen, raloxifene, anastrozole, adriamycin, Cytoxan, paclitaxel, carboplatin, navelbine		
Pancreas	PR	gemcitabine, 5-FU, oxaliplatin	7	
Part 2	(n=28)			
Breast	PR	adriamycin, cytoxan, paclitaxel, capecitabine, irinotecan, ABT-888 (PARP inhibitor), MPDL3280A	>19	
Ovary	SD	paclitaxel, carboplatin, doxil	22	
Breast	SD	adriamycin, cytoxan, capecitabine, faslodex	12	
Ovary	SD	paclitaxel, carboplatin, doxil, gemcitabine, topotecan, cytoxan, avastin	11	
Ovary	SD	paclitaxel, carboplatin, doxil, olaparib (PARP inhibitor), cediranib	8	
Ovary	SD	paclitaxel, carboplatin	4	
Ovary	SD	paclitaxel, carboplatin, doxil, gemcitabine, alimta, cytoxan, avastin, olaparib (PARP inhibitor)		
Pancreas	PR	gemcitabine, abraxane, docetaxel	4	
Pancreas	SD	gemcitabine, cisplatin, abraxane, folfox, TH-302	4	

ED AT ASCO ANNUAL MEETING '16


Presented by: Sara M. Tolaney, MD, MPH

* Source: Tolaney S et al, JCO 34, 2016 (suppl; abs. 2503).





Best Response (all cycles)



* Source: Tolaney S et al, JCO 34, 2016 (suppl; abs. 2503).



* Source: Tolaney S et al, J Clin Oncol 34, 2016 (suppl; abstr 2503); Shapiro et al, AACR Proceedings, 2013, LB-202. HR=homologous recombination. # sinale-strand breaks

DDR Strategy: sapacitabine + CDK inhibitor

All-oral, low toxicity regimen

- Parts 1 & 2 durable benefit (CR, PRs & SD) in
 BRCA+ve breast, ovarian, pancreatic cancers
- Part 3 ongoing: revised schedule including
 BRCA +ve ovarian, pancreatic cancer patients

Potentially substitute CYC065 in lieu of seliciclib









Sapacitabine in AML

Sapacitabine in AML (SEAMLESS Ph 3 data)

Optionality from potential regulatory submission




- ✓ Increase in median OS (primary endpoint) did not reach stat. sig.
- ✓ Doubling of CR rate (secondary endpoint)
- ✓ Improved median OS in large (2/3 of study) prospectively defined subgroup based on WBC level
- ✓ Oral presentation at ASH Annual Meeting 2017
- Determine optimal cut-off for WBC
- Determine submissibility to regulatory authorities
- Pre-submission End of Phase 3 meetings

Source: Cyclacel press releases and data on file.

Survival - Baseline WBC <10,000







* Source: Kantarjian H, et al, American Society of Hematology Annual Meeting Dec. 2017, Abstract #891.

Development Pipeline



Program CYC	Target/Indication	Preclinical	Phase 1/1b	Phase 2	Pivotal	Comm. Rights	
	Solid tumors (FIH)	RP2D Part	2 ongoing				
005	Blood cancers <i>CLL + Bcl-2 inhibitor</i>	CYC065 + ven	etoclax RR CLL			Worldwide	
065	Solid tumors, i.e. NB MYCN, Mcl-1, Cyc E		Ph	1/2			
	Oral formulation	СМС	> Ph1 Oral				
6202	DDR*: BRCA Breast,ovarian,pancr.	sapa + seliciclib Part 3 ongoing		Worldwide (except Japan)			
sapa	SEAMLESS Data <i>AML</i>	Determine submissibilty; regulatory advice (e.					
140	Solid tumors and blood cancers	IND-ready	Ph1 FIH			Worldwide	
Current activity In planning stage							



Financials



Sept 30, 2017 cash & cash equivalents: \$26.0m¹

Current Operating cash burn (excludes non-cash items)

✓ 2014:	~ \$18.7m annual ²
✓ 2015:	~ \$14.5m annual ²
✓ 2016:	~ \$10.1m annual ²
	2

2017: ~ \$ 8.0m annual ³

Fully diluted shares: ~ 20.0 million^{1,4}

No debt

- 1. 10Q
- 2. 10-К
- 3. Company estimate
- 4. Common stock outstanding: 11.9m



- Start CYC065 Ph 1b in RR CLL combo with venetoclax
- Start CYC065 Phase 1/2 in solid tumors, incl. NB
- CYC065 Phase 1 data solid tumors
- CYC065 oral formulation development
- Sapacitabine/seliciclib update BRCA +ve breast cancer
- CYC140 (PLKi) IND submission
- Determine submissibility of sapacitabine in eAML

Investment Thesis

- Clinical stage CDKi and DDR oncology programs
- Targeting molecularly-defined patient populations
- Treat difficult cancers and overcome cancer cell resistance & DNA repair
- CDK inhibitors: validated drug class
- Competitively positioned
- Significant market opportunities







THANK YOU

Cyclacel Pharmaceuticals, Inc.

200 Connell Drive #1500 Berkeley Heights, NJ 07922 +1 (908) 517 7330

Contact: ir@cyclacel.com